Ofloxacin Devatis

Ofloxacin, the active ingredient in Ofloxacin Devatis, is a fluoroquinolone antibiotic presented as an intraocular ophthalmic solution for the treatment of bacterial eye infections. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial replication in patients with conjunctival or corneal involvement.

GNH USA supplies Ofloxacin Devatis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for importers.

Ofloxacin is indicated for bacterial eye infections, acting on the ocular surface and cornea to eradicate susceptible pathogens. - Bacterial conjunctivitis: reduces bacterial load and accelerates symptom resolution in acute conjunctival infection. - Keratitis: treats bacterial corneal inflammation, helping to prevent ulceration and preserve visual acuity. - Other bacterial eye infections: effective against a range of ocular pathogens causing blepharitis, dacryocystitis, or postoperative infections.

Ophthalmic administration of Ofloxacin may be associated with local and systemic adverse reactions. Common Side Effects: - Eye irritation: transient burning or stinging upon instillation. - Redness: mild conjunctival hyperemia. - Tearing: increased lacrimation. Serious or Rare Side Effects: - Corneal ulceration: worsening of corneal lesions requiring immediate discontinuation. - Severe allergic reaction: eyelid edema, rash, or anaphylaxis. - Tendonitis or tendon rupture: rare systemic effect especially in susceptible patients.

When prescribing intraocular Ofloxacin, clinicians should consider several precautionary measures to ensure safety and efficacy. - Allergy assessment: verify no known hypersensitivity to fluoroquinolones or other ophthalmic antibiotics. - Contact lens use: advise patients to remove lenses before instillation and avoid wearing them for at least 15 minutes after dosing. - Concurrent ocular disease: monitor patients with pre‑existing corneal epithelial defects closely. - Systemic absorption: be aware of potential systemic fluoroquinolone effects in patients with renal impairment. - Pregnancy and lactation: use only if the potential benefit outweighs the unknown risk, as safety data are limited. - Store at ambient temperature: keep the product below 25 °C, in the original container, protected from light and moisture.

Ofloxacin may interact with other medicines; awareness of significant interactions helps prevent reduced efficacy or increased toxicity. Major Interactions (Avoid): - Systemic fluoroquinolones: concurrent use may increase risk of tendon toxicity and CNS effects. - Antacids or multivitamins containing aluminum, magnesium, calcium, or iron: can chelate the drug and markedly reduce ocular absorption. - Corticosteroids: may potentiate risk of corneal perforation when combined with fluoroquinolone eye drops. Moderate Interactions (Monitor Closely): - Cyclosporine ophthalmic drops: monitor for additive ocular irritation. - Warfarin: systemic absorption may enhance anticoagulant effect; check INR if long‑term use is anticipated. - Diabetes medications: rare reports of dysglycemia; observe blood glucose if systemic exposure is suspected.